All stories

1 outlets · filed 10 November 2026

FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss

This story is from the archive. It was covered between 10 November 2026 and 10 November 2026, and nothing below has been updated since. See what is happening now.

The risk appears small and data is mixed, but FDA wants patients to be aware.

What the coverage shows

All five outlets center on the FDA warning that GLP-1 drugs may be linked to a rare eye condition that can cause serious vision loss or blindness. BBC News and The Guardian US are the only ones to foreground labeling changes, with BBC saying makers were ordered to add warnings and The Guardian saying the FDA is requiring all GLP-1s to include the risk on warning labels. Ars Technica uniquely stresses that the risk appears small and the data are mixed, while CNBC frames it as evidence of a potential increased risk.

Written by Crossfiled from the 1 headlines and extracts below, not from the articles themselves. It describes how the outlets framed this, not what happened. Open any headline for a summary of that article.

Ars Technica

How it broke

In this story

1outlets
0videos
1articles

More on Health

Every Health story, across every outlet